Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BHST NASDAQ:CING NASDAQ:MCRB NASDAQ:QNTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHSTBioHarvest Sciences$3.20$3.97$3.02▼$12.80$62.77M0.724,522 shs15,154 shsCINGCingulate$4.88-4.1%$5.04$3.16▼$11.89$65.73M-0.85815,741 shs179,262 shsMCRBSeres Therapeutics$5.70-9.8%$7.80$5.63▼$29.98$55.20M0.1358,498 shs109,370 shsQNTMQuantum Biopharma$3.83-4.3%$4.98$2.07▼$38.25$14.62M0.36484,354 shs118,131 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHSTBioHarvest Sciences0.00%+0.31%-20.20%-22.89%-56.04%CINGCingulate-4.13%+8.69%-0.81%-43.84%+5.40%MCRBSeres Therapeutics-9.81%-14.03%-26.55%-33.95%-29.02%QNTMQuantum Biopharma-4.25%-10.09%-29.98%+54.44%-75.08%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHSTBioHarvest Sciences$3.20$3.97$3.02▼$12.80$62.77M0.724,522 shs15,154 shsCINGCingulate$4.88-4.1%$5.04$3.16▼$11.89$65.73M-0.85815,741 shs179,262 shsMCRBSeres Therapeutics$5.70-9.8%$7.80$5.63▼$29.98$55.20M0.1358,498 shs109,370 shsQNTMQuantum Biopharma$3.83-4.3%$4.98$2.07▼$38.25$14.62M0.36484,354 shs118,131 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHSTBioHarvest Sciences0.00%+0.31%-20.20%-22.89%-56.04%CINGCingulate-4.13%+8.69%-0.81%-43.84%+5.40%MCRBSeres Therapeutics-9.81%-14.03%-26.55%-33.95%-29.02%QNTMQuantum Biopharma-4.25%-10.09%-29.98%+54.44%-75.08%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHSTBioHarvest Sciences 2.00Hold$10.00212.50% UpsideCINGCingulate 2.50Moderate Buy$27.33460.11% UpsideMCRBSeres Therapeutics 2.00Hold$22.00285.96% UpsideQNTMQuantum Biopharma 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest QNTM, BHST, CING, and MCRB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/8/2026CINGCingulate Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$55.00 ➝ $52.006/3/2026BHSTBioHarvest Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/28/2026QNTMQuantum Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/26/2026CINGCingulate HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.005/22/2026CINGCingulate Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/19/2026CINGCingulate Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.005/18/2026MCRBSeres Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/14/2026QNTMQuantum Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/20/2026CINGCingulate Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026CINGCingulate Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$58.00 ➝ $55.003/27/2026BHSTBioHarvest Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHSTBioHarvest Sciences$34.51M1.82N/AN/A$1.30 per share2.46CINGCingulateN/AN/AN/AN/A$0.31 per shareN/AMCRBSeres Therapeutics$790K69.84$0.98 per share5.82$4.89 per share1.17QNTMQuantum BiopharmaN/AN/AN/AN/A$1.34 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHSTBioHarvest Sciences-$11.14M-$0.59N/AN/AN/A-32.54%-76.03%-25.30%8/10/2026 (Estimated)CINGCingulate-$22.45M-$4.23N/AN/AN/AN/A-365.15%-158.55%8/18/2026 (Estimated)MCRBSeres Therapeutics$5.70M-$5.17N/AN/AN/AN/A-130.29%-35.35%8/5/2026 (Estimated)QNTMQuantum Biopharma-$26.17M-$8.25N/AN/AN/AN/A-941.54%-224.41%8/6/2026 (Estimated)Latest QNTM, BHST, CING, and MCRB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026BHSTBioHarvest Sciences-$0.13-$0.11+$0.02-$0.11$8.50 million$8.51 million5/14/2026Q1 2026CINGCingulate-$0.53-$0.95-$0.42-$0.95N/AN/A5/5/2026Q1 2026MCRBSeres Therapeutics-$1.88-$2.08-$0.20-$2.08$0.36 million$0.36 million4/1/2026Q4 2025BHSTBioHarvest Sciences-$0.11-$0.10+$0.01-$0.10$9.24 million$9.07 million3/26/2026Q4 2025QNTMQuantum Biopharma-$0.22-$0.71-$0.49-$0.71$2.17 millionN/A3/18/2026Q4 2025CINGCingulate-$0.56-$0.84-$0.28-$0.84N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBHSTBioHarvest SciencesN/AN/AN/AN/AN/ACINGCingulateN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/AQNTMQuantum BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHSTBioHarvest Sciences0.032.962.44CINGCingulateN/A2.552.55MCRBSeres TherapeuticsN/A1.651.65QNTMQuantum BiopharmaN/A0.630.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHSTBioHarvest SciencesN/ACINGCingulate41.31%MCRBSeres Therapeutics59.34%QNTMQuantum Biopharma1.24%Insider OwnershipCompanyInsider OwnershipBHSTBioHarvest SciencesN/ACINGCingulate5.30%MCRBSeres Therapeutics5.20%QNTMQuantum Biopharma8.53%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHSTBioHarvest SciencesN/A19.62 millionN/AN/ACINGCingulate2013.47 million12.76 millionNot OptionableMCRBSeres Therapeutics3309.68 million9.18 millionOptionableQNTMQuantum BiopharmaN/A3.82 million3.49 millionN/AQNTM, BHST, CING, and MCRB HeadlinesRecent News About These CompaniesQuantum BioPharma (QNTM) Advances Proprietary Therapy for MS TreatmentJune 9, 2026 | finance.yahoo.comQuantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Builds Diversified Pipeline Across Neurological and Wellness MarketsJune 5, 2026 | markets.businessinsider.comQuantum BioPharma (QNTM) Builds Diversified Pipeline Across Neurological and Wellness MarketsJune 5, 2026 | finance.yahoo.comQuantum BioPharma (QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire PodcastJune 3, 2026 | finance.yahoo.comIBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.June 2, 2026 | globenewswire.comQuantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation CampaignsJune 2, 2026 | globenewswire.comQuantum Biopharma (NASDAQ:QNTM) Stock Price Down 23.5% - What's Next?June 2, 2026 | americanbankingnews.comQuantum BioPharma Provides Corporate UpdateJune 1, 2026 | globenewswire.comQuantum BioPharma (QNTM) Reports Midpoint Enrollment Milestone in MS Imaging StudyMay 20, 2026 | finance.yahoo.comQuantum BioPharma shares climb as multiple sclerosis imaging study advances (QNTM)May 18, 2026 | msn.comQuantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reports Midpoint Enrollment Milestone in MS Imaging StudyMay 18, 2026 | markets.businessinsider.comQuantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General HospitalMay 18, 2026 | globenewswire.comQuantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in ...May 7, 2026 | caledonianrecord.comCQuantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026May 7, 2026 | globenewswire.comQuantum BioPharma (QNTM) price target increased by 10.88% to 36.72April 28, 2026 | msn.comQuantum BioPharma Provides Corporate UpdateApril 27, 2026 | globenewswire.comQuantum BioPharma Ltd.April 24, 2026 | barrons.comQuantum BioPharma’s Unbuzzd Licensee Names New CEO to Drive U.S. Rollout of Clinically Backed Hangover BeverageApril 24, 2026 | theglobeandmail.comQuantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and ...April 24, 2026 | markets.businessinsider.comQuantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism AccelerantApril 22, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMicron’s $1 Trillion Memory Melt-UpBy Jeffrey Neal Johnson | May 27, 2026IREN's 800MW Bet Flips the AI Power SwitchBy Jeffrey Neal Johnson | June 6, 2026Vertical Aerospace: Pre-Flight Checks Point to a BreakoutBy Jeffrey Neal Johnson | May 20, 2026RTX Is Set to Revolutionize Munitions ManufacturingBy Jeffrey Neal Johnson | May 28, 2026The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May AppearBy Chris Markoch | May 25, 2026QNTM, BHST, CING, and MCRB Company DescriptionsBioHarvest Sciences NASDAQ:BHST$3.20 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$3.26 +0.06 (+2.03%) As of 06/12/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.Cingulate NASDAQ:CING$4.88 -0.21 (-4.13%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$4.96 +0.08 (+1.66%) As of 06/12/2026 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Seres Therapeutics NASDAQ:MCRB$5.70 -0.62 (-9.81%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$6.10 +0.41 (+7.11%) As of 06/12/2026 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Quantum Biopharma NASDAQ:QNTM$3.83 -0.17 (-4.25%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$3.90 +0.06 (+1.70%) As of 06/12/2026 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears This Energy Stock Has Quietly Soared 130% in a Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
